You can buy or sell AQST and other stocks, options, ETFs, and crypto commission-free!
Aquestive Therapeutics, Inc. Common Stock, also called Aquestive Therapeutics, is a specialty pharmaceutical company focused on identifying, developing, and commercializing differentiated products to address unmet medical needs. Read More The company has a late-stage proprietary product pipeline focused on the treatment of Central nervous system (CNS) diseases, as well as orally-administered complex molecules that can be alternatives to invasively-administered standard of care therapies. Its product candidates include Libervant, Sympazan, and AQST-117 (Riluzole). Aquestive Therapeutics develops and delivers drugs via its PharmFilm® technology. The firm also collaborates with pharmaceutical partners to bring new molecules to market in differentiated and highly-marketable dosage forms. In addition to its proprietary product candidates, the company, with its partners, has a portfolio of development-stage products and commercialized products, such as Suboxone, a prescription medicine for the treatment of opioid dependence. The company was founded in January 2004 and is headquartered in Warren, NJ.
Warren, New Jersey
52 Week High
52 Week Low
Yahoo FinanceMay 13
Aquestive Therapeutics to Present at Two Upcoming Investor Conferences
WARREN, N.J., May 13, 2019 /PRNewswire/ -- Aquestive Therapeutics, Inc. (AQST), a specialty pharmaceutical company focused on developing and commercializing differentiated products that meet patients' unmet needs and solve therapeutic problems, today announced that management will present at the 2019 RBC Capital Markets Global Healthcare Conference to be held in New York, NY on May 21-22, and the 20th Annual B. Riley FBR Institutional Investor Conference to be held in Beverly Hills, CA on May 22-23. Present...
Seeking AlphaMay 11
Aquestive Therapeutics, Inc. CEO Keith Kendall on Q1 2019 Results - Earnings Call Transcript
Aquestive Therapeutics, Inc. (NASDAQ:AQST) Q1 2019 Earnings Conference Call May 8, 2019 8:00 AM ET Company Participants Lauren Walrath - Head, Corporate Marketing and Communications Keith Kendall - Chief Executive Officer Ken Marshall - Chief Commercial Officer Daniel Barber - Chief Strategy and Development Officer John Maxwell - Chief Financial Officer Conference Call Participants Randall Stanicky - RBC Capital Markets Liana Moussatos - Wedbush Securities Thomas Flaten - Lake Street Capital Ram ...
Yahoo FinanceMay 8
Aquestive Therapeutics: 1Q Earnings Snapshot
WARREN, N.J. (AP) _ Aquestive Therapeutics Inc. (AQST) on Wednesday reported a loss of $14.7 million in its first quarter. On a per-share basis, the Warren, New Jersey-based company said it had a loss of 59 cents. The specialty pharmaceutical company posted revenue of $12.6 million in the period. Aquestive Therapeutics shares have fallen 13% since the beginning of the year. _____ This story was generated by Automated Insights (http://automatedinsights.com/ap) using data from Zacks Investment Research. ...
-$0.50 per share
-$0.59 per share